Publications
182
Citations
6,057
Est. group size
~2
Recurring co-author estimate
Active years
61
Publishing since 1966
John H. Howard's research focuses on surgical oncology, particularly the treatment and outcomes of melanoma (skin cancer), sarcoma (cancer of connective tissue), and liver cancer (hepatocellular carcinoma). His work includes clinical trials of localized chemotherapy delivery systems, studies on prognostic factors and recurrence risk, and evaluations of how well clinical guidelines are followed in cancer care. This research is likely relevant to students interested in surgical oncology, clinical trials, and cancer outcomes research.
Publication output rose to a peak around 2020, has generally slowed since then, averaging under 6 papers per year over the last five years.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Assessment of recurrence risk in stage IIB/C melanoma across time: Implications for stratification and surveillance.
Journal of Clinical Oncology · 2026
- An Open-label, Randomized Study of Melphalan/Hepatic Delivery System Versus Best Alternative Care in Patients with Unresectable Metastatic Uveal Melanoma
Annals of Surgical Oncology · 2025
- Tumor infiltrating lymphocytes in primary melanoma are associated with a better prognosis
The American Journal of Surgery · 2025
- External validation of a model to predict recurrence-free and melanoma-specific survival for patients with melanoma after sentinel node biopsy
British journal of surgery · 2025
- Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study
Annals of Surgical Oncology · 2024
- Stage-Based Detection Methods and Recurrence Patterns for Cutaneous Melanoma
The American Surgeon · 2024
- ASO Visual Abstract: Efficacy and Safety of Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter, Phase 3 Study
Annals of Surgical Oncology · 2024
- Correction: Efficacy and Safety of the Melphalan/Hepatic Delivery System in Patients with Unresectable Metastatic Uveal Melanoma: Results from an Open-Label, Single-Arm, Multicenter Phase 3 Study
Annals of Surgical Oncology · 2024
- Rescue Rates for Talimogene laherparepvec Use in Loco-Regionally Progressing Cutaneous Melanoma Refractory to PD1 Inhibition
The American Surgeon · 2024
- Four Cases of Acute Kidney Injury Requiring Dialysis in Ultramarathoners
Wilderness and Environmental Medicine · 2023
- The adherence to the American Association for the Study of Liver Diseases 2018 guidelines in the management of hepatocellular carcinoma and its impact on survival
Journal of Cancer Research and Therapeutics · 2023
- TIMP-1 Dependent Modulation of Metabolic Profiles Impacts Chemoresistance in NSCLC
Cells · 2022
- Cemiplimab in advanced cutaneous squamous cell carcinoma: A real-world experience of outcomes and safety.
Journal of Clinical Oncology · 2022
- ASO Author Reflections: Utility of Prognostic Nomograms for Extremity Soft Tissue Sarcoma
Annals of Surgical Oncology · 2022
- Clinical and Hematological Predictors of High-Grade Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors
Journal of Clinical Medicine Research · 2021
- Annals of Surgical Oncology×12
- Journal of Surgical Oncology×11
- Journal of Surgical Research×7
- Cancer Research×4
- The American Surgeon×4
- Bhuvana A. Setty
Medicine · The Ohio State University
- Bonita Fung
Medicine · The Ohio State University
- Archana Shenoy
Medicine · The Ohio State University
- Ashley Patton
Medicine · The Ohio State University
- Christopher D. Collier
Medicine · Indiana University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile